CRIPTO3 and Huntington disease: To our knowledge, our study provides the first in vivo evidence to validate targeting complement component C1q and complement receptor CR3 to prevent synapse loss and improve cognitive function in HD mouse models, and it strengthens the rationale for developing complement-related therapeutics, including the anti-C1q antibody ANX005.